# Gery Lefebvre

> Gery Lefebvre is a grant investor at S.R.I.W. backing Biotechnology and Medical. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [S.R.I.W.](https://shizune.co/investors/profile/s-r-i-w)
- Total investments: 2
- Last investment: Mar 2026
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/gery-lefebvre-21007213/

Gery Lefebvre is a grant investor at S.R.I.W. focused on Biotechnology and Medical. Gery Lefebvre - Investment Manager @ S.R.I.W.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Medical | 1 | 50% |
| Genetics | 1 | 50% |
| Health Care | 1 | 50% |
| Pharmaceutical | 1 | 50% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 1 | 50% |
| Series B | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Spain | 1 | 50% |
| United States | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| VolitionRx | Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid which is an indication that disease ispresent.As cancer screening programs become more and more widespread, its products aim to help to diagnose a range of cancers quickly, simply, accurately, and cost-effectively. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life.Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and worldwide. | $2.3M | Grant | Mar 31, 2026 |  |
| Minoryx Therapeutics | Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promisingapproach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects. | $23.4M | Series B | Sep 26, 2018 |  |

2 of 2 investments shown.

## Co-investors
- [Criteria Venture Tech](https://shizune.co/investors/profile/caixa-capital) — VC Fund, 1 deal together
- [Fund+](https://shizune.co/investors/profile/fund) — VC Fund, 1 deal together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 1 deal together
- [Namur Invest](https://shizune.co/investors/profile/namur-invest) — VC Fund, 1 deal together
- [Roche Venture Fund](https://shizune.co/investors/profile/roche-venture-fund) — VC Fund, 1 deal together
- [Sambrinvest](https://shizune.co/investors/profile/sambr-invest) — VC Fund, 1 deal together

## About S.R.I.W.

VC Fund · Liège, Belgium

The S.R.I.W. Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st century. Since its creation in 1979, the Société Régionaled’Investissement de Wallonie has continuously been expanding its abilities to adapt and anticipate as well as its flexibility in order to meet the requirements of its partners who are confronted with the evolution of the world economy. The principles of good governance, a strong business culture and shared values at the heart of the Group constitute important assets to capture the changing realities of the market and progress in a sustainable development perspective.

5 contacts available at S.R.I.W..

| Name | Title | Profile |
| --- | --- | --- |
| Damien Lourtie | Chief Financial Officer | https://shizune.co/investors/profile/damien-lourtie |
| Gery Lefebvre | Investment Manager | https://shizune.co/investors/profile/gery-lefebvre |
| Jean-Pascal LABILLE | Chairman | https://shizune.co/investors/profile/jean-pascal-labille |
| Philippe Degive | Investment Manager | https://shizune.co/investors/profile/philippe-degive |
| Thibaut Claes | Investment Manager | https://shizune.co/investors/profile/thibaut-claes |

## Similar investors

### Similar stage
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund

## FAQ

### What does Gery Lefebvre invest in?

Gery Lefebvre invests primarily in Biotechnology, Medical and Genetics startups, most often at Grant and Series B stage. Most of the 2 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Gery Lefebvre last invest?

The most recent investment recorded for Gery Lefebvre closed in Mar 2026. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co